Branded or Generic? Adults Share Preferences in Study

mia.burns By Mia Burns (mia.burns@ubm.com) Close to 16 percent, or 37 million of adults agree that paying more for branded prescription medications rather than getting generic products, ...

AbbVie’s veliparib wows in a breast cancer study

Damian Garde AbbVie's PARP inhibitor veliparib improved outcomes for women with triple-negative breast cancer in a new investigator-sponsored study, charting a 52% complete response ...

Zafgen lands $45M round for obesity drug study

John Carroll FierceBiotech News

Keryx Updates on Ongoing Zerenex Study

mia.burns Keryx Biopharmaceuticals Provides Update From Ongoing Zerenex(TM) (ferric citrate coordination complex) Long-Term Safety Extension Study in Patients With Hyperphosphatemia ...

JAMA study raises red flag on big-selling testosterone drugs

Tracy Staton As more and more baby boomers have signed on for testosterone testing–and, in turn, therapy–worries about the safety of testosterone-boosting drugs have ...

Ocera raises $28M for PhIIb liver disease study

John Carroll Ocera Therapeutics raised $ 28 million from a group of venture investors backing the biotech's work on orphan liver diseases. The San Diego-based biotech's lead ...

Study: Drug developers routinely–and unethically–leave trial data in the dark

John Carroll Drug companies routinely herald their concern for patients as the leading reason why they spend billions of dollars on drug research. But a new study questions Big Pharma's ...

Study: R&D for neglected diseases still negligible

Damian Garde Despite some high-profile commitments from some of the industry's largest innovators, R&D for some of the world's most deadly neglected diseases remains underfunded ...

Hopkins study reports setback in HIV/AIDS cure

Emily Mullin New research suggests that a cure for HIV/AIDS may be much further off that scientists believed, underscoring the need for different drug approaches. FierceBiotech News

New study raises new questions about Merck cholesterol drug

Tracy Staton A new study finds that the drug lingers in the bodies of patients long after they've stopped using it, sometimes even for years. FiercePharma News

AstraZeneca launches PhIII lung cancer study in late-stage rebuilding effort

John Carroll A decade after obtaining the rights to the cancer drug selumetinib from Array Biopharma, the hungry pharma giant AstraZeneca is moving the MEK inhibitor into a late-stage ...

Study: Online Consumer Health Engagement Expanding

mia.burns By Mia Burns (mia.burns@ubm.com) Consumer use of health websites and other online tools to collect information about conditions and treatments is not a new trend, but now ...
Page 3 of 1312345...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS